Urinary basement membrane graft-augmented sacrospinous ligament suspension: a description of technique and short-term outcomes
- PMID: 35294566
- DOI: 10.1007/s00192-022-05159-9
Urinary basement membrane graft-augmented sacrospinous ligament suspension: a description of technique and short-term outcomes
Abstract
Introduction and hypothesis: Since the discontinuation of manufacture and distribution of surgical mesh for transvaginal prolapse repair, the use of biologic grafts for transvaginal apical suspension has gained renewed attention. However, there is no FDA-approved device and minimal published data describing such an approach. The objective of this video is to describe a technique and to present limited short-term outcomes utilizing a porcine urinary basement membrane (UBM) graft to perform an augmented bilateral sacrospinous ligament suspension (SSLS).
Methods: We present a step-by-step overview of our technique to perform an augmented SSLS with off-label utilization of a 7- × 10-cm porcine UBM graft. We demonstrate graft shaping and application during transvaginal repair along with data describing perioperative outcomes associated with a series of 25 cases performed at our institution using the technique described.
Results: No perioperative complications related to the graft were observed in our cohort. The most common postoperative concern was buttock pain, which spontaneously resolved within 6 months. Two individuals (8%) developed recurrent prolapse within 1 year of surgery.
Conclusions: The UBM-augmented apical suspension allows for reinforced transvaginal prolapse repair without the use of permanent mesh material. We have observed good clinical success in our application of this technique, but dedicated research assessing long-term outcomes compared with a native tissue repair is needed.
Keywords: Sacrospinous ligament suspension; Urinary basement membrane graft; Vaginal prolapse repair.
© 2022. The International Urogynecological Association.
References
-
- US Food and Drug Administration. FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices. 2017. https://www.fda.gov/news-events/press-announcements/fda-takes-action-pro... . Accessed 27 Jan 2021
-
- Ng-Stollmann N, Funfgeld C, Gabriel B, Niesel A. The international discussion and the new regulations concerning transvaginal mesh implants in pelvic organ prolapse surgery. Int Urogynecol J. 2020;31(10):1997–2002. https://doi.org/10.1007/s00192-020-04407-0 . - DOI - PubMed - PMC
-
- Glazener CM, Breeman S, Elders A, et al. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT). Lancet. 2017;389(10067):381–92. https://doi.org/10.1016/S0140-6736(16)31596-3 . - DOI - PubMed
-
- Winkelman WD, Macharia A, Bharadwa S, Bharadwaj M, Hacker MR, Rosenblatt PL. Composite outcomes after posterior colporrhaphy with and without biologic graft augmentation. Female Pelvic Med Reconstr Surg. 2021;27(2):e414–7. https://doi.org/10.1097/SPV.00000000000009495 . - DOI - PubMed - PMC
-
- Brown BN, Londono R, Tottey S, et al. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater. 2012;8(3):978–87. https://doi.org/10.1016/j.actbio.2011.11.031 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
